Ad-powered AI startup OpenEvidence expands global reach and faces mixed clinical validation

OpenEvidence, a $15 billion ad-powered AI startup, has expanded its reach to 100 low- and middle-income countries, supported by Anthropic's Claude Science platform for literature mining. While a Mayo Clinic study found it provided accurate, evidence-based recommendations in sampled patient cases, other research, including a June paper in Nature, showed it underperformed general-purpose AI models like Google’s Gemini and OpenAI’s GPT on clinical benchmarks. Eric Oermann, a neurosurgeon at NYU Langone, noted a lack of research on individual AI tool performance and guidance for clinical implementation.